Working with academic collaborators at the University of Oxford, PHE Porton Down has been evaluating the performance of lateral flow devices (LFDs) since mid-August 2020. Over 80 have been considered to date, approximately 30% of which have progressed to extended evaluation on clinical samples at Phase 3.
Source link
